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HLA genotyping and genome wide association studies provide strong evidence for associations between Human Leukocyte Anti-
gen (HLA) alleles and classical Hodgkin lymphoma (cHL). Analysis of these associations is complicated by the extensive linkage
disequilibrium within the major histocompatibility region and recent data suggesting that associations with EBV-positive and
EBV-negative cHL are largely distinct. To distinguish independent and therefore potentially causal associations from associa-
tions confounded by linkage disequilibrium, we applied a variable selection regression modeling procedure to directly typed
HLA class I and II genes and selected SNPs from EBV-stratified patient subgroups. In final models, HLA-A*01:01 and B*37:01
were associated with an increased risk of EBV-positive cHL whereas DRB1*15:01 and DPB1*01:01 were associated with
decreased risk. Effects were independent of a prior history of infectious mononucleosis. For EBV-negative cHL the class II SNP
rs6903608 remained the strongest predictor of disease risk after adjusting for the effects of common HLA alleles. Associations
with “all cHL” and differences by case EBV status reflected the subgroup analysis. In conclusion, this study extends previous
findings by identifying novel HLA associations with EBV-stratified subgroups of cHL, highlighting those alleles likely to be bio-
logically relevant and strengthening evidence implicating genetic variation associated with the SNP rs6903608.
Classical Hodgkin lymphoma (cHL) is a B-cell derived malig-
nancy, which is one of the most common cancers of young
adults.1,2 It is unusual in that the tumor cells, the Hodgkin
and Reed-Sternberg (HRS) cells, constitute only a small frac-
tion of the tumor mass, which is dominated by a mixed cel-
lular inﬁltrate containing a high proportion of T-cells.3
Interactions between HRS cells and the microenvironment
are thought to play a major role in disease pathogenesis.3
Epstein-Barr virus (EBV) is causally associated with approxi-
mately one third of cases in socioeconomically developed
countries.4,5 In EBV-positive cases, HRS cells express a group
of EBV latent antigens comprising EBV nuclear antigen
(EBNA1) and latent membrane protein (LMP) 1, 2A and
2B.4 Whilst these proteins have a plausible role in disease
Key words: Hodgkin lymphoma, EBV, HLA
Abbreviations: cHL: classical Hodgkin lymphoma; CI: confidence interval; CTL: cytotoxic T-lymphocyte; EBNA: EBV nuclear antigen;
EBV: Epstein-Barr virus; EBER: Epstein-Barr virus-encoded small RNA; GWAS: genome wide association study or studies; HLA: human
leukocyte antigen; HRS: Hodgkin and Reed-Sternberg; IM: infectious mononucleosis; LD: linkage disequilibrium; LMP: latent membrane
protein; MHC: major histocompatibility complex; OR: odds ratio; PPA: posterior probability of association; SNEHD: Scotland and New-
castle Epidemiological study of Hodgkin lymphoma; SNP: single nucleotide polymorphism
Additional Supporting Information may be found in the online version of this article.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is properly cited.
Grant sponsor: Leukaemia Lymphoma Research grants; Grant number: 08031 and 12022; Grant sponsor: Kay Kendall Leukaemia Fund
DOI: 10.1002/ijc.29467
History: Received 26 Sep 2014; Accepted 8 Jan 2015; Online 3 Feb 2015
Correspondence to: Ruth F Jarrett, Ian Botham Building, Garscube Estate, University of Glasgow, Glasgow, G61 1QH, United Kingdom,
Tel.: [441413305775], Fax: 1[44-141-330-5733], E-mail: ruth.jarrett@glasgow.ac.uk
C
an
ce
r
G
en
et
ic
s
Int. J. Cancer: 00, 00–00 (2015) VC 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC.
International Journal of Cancer
IJC
pathogenesis,4 they elicit only weak cytotoxic T-cell (CTL)
responses.6 In a small proportion of patients, EBV-positive
cHL occurs following infectious mononucleosis (IM), a dis-
ease associated with delayed infection by EBV.729
Susceptibility to Hodgkin lymphoma was ﬁrst associated
with Human Leukocyte Antigen (HLA) genes within the
Major Histocompatibility Complex (MHC) in the 1960 s10;
however, associations with HLA alleles, including HLA-A1,11
proved difﬁcult to verify due to small sample sizes and low-
resolution typing methods. Subsequently, the development of
molecular typing methods revealed associations with the
HLA class II alleles HLA-DPB1*02:01 and HLA-
DPB1*03:01.12216 Klitz et al. (1994) also described links
between the nodular sclerosis subtype of cHL and multiple
class II haplotypes including DRB1*15:01-DQA1*01:02-
DQB1*06:02.17 Within the last decade, several studies have
shown that HLA-A*01:01 and A*02:01 are associated with an
increased and decreased risk of EBV-positive cHL,
respectively.18221 Recently, Huang et al. (2012) described
associations between EBV-positive cHL and HLA-B37 and
DR10, but suggested that these were most probably due to
linkage disequilibrium (LD) with HLA-A1 on the haplotype
HLA-A1-B37-DR10.22 They also reported that DR2 (the sero-
type that includes DRB1*15) and DR5 were associated with
an increased risk and DR7 with a decreased risk of EBV-
negative cHL.22 However, because their analysis used allele
frequencies rather than individual genotypes they could not
separate potentially causative associations from confounding
due to LD in a mutually adjusted analysis. In addition, case:
control analysis of DPB1 alleles was not performed.
Genome-wide association studies (GWAS) have revealed
striking associations between cHL and single nucleotide poly-
morphisms (SNPs) in the MHC region, with the class II SNP
rs6903608 showing the strongest association with disease.23226
In the only GWAS to stratify patients by EBV status in the dis-
covery analysis, ﬁve MHC SNPs were independently associated
with cHL.24 These included: two class I SNPs that were associ-
ated with EBV-positive cHL and accounted for by effects of
A*01:01 and A*02:01; rs6903608, a class II SNP, which was
associated with EBV-negative cHL; and rs2248462 and
rs2395185 which did not show heterogeneity by EBV status.
Moutsianas et al. (2011) analysed HLA-A, C, B, DRB1, DQA1
and DQB1 alleles imputed from their GWAS data, but did not
stratify patients by EBV status.27 In unconditional analyses, an
increased risk of cHL was associated with DRB1*15:01,
DQB1*06:02 and DQB1*03:03 and a decreased risk with
DRB1*07:01 and DQA1*02:01; however, the effect of rs6903608
could not be explained by these alleles and they concluded that
rs6903608, DQA1*02:01 and the DPB1 SNP rs2281389 were
the main independent contributors to disease risk.
The above studies show clear associations between MHC
polymorphisms and risk of cHL but, as yet, no single study
has performed a mutually adjusted analysis of both HLA
alleles and SNPs with cases stratiﬁed by EBV status. The aim
of this study was to identify alleles likely to have a biological
role in cHL pathogenesis by applying a variable selection
modeling procedure to directly typed HLA class I and II
genes, including DPB1, from EBV-stratiﬁed subgroups of
patients. The three SNPs that contribute independently to
disease risk, but have not been accounted for by effects of
HLA alleles, were also included in these analyses.
Material and Methods
Participants
The cHL patients included in this analysis have been
described previously21 and were from two epidemiological
studies and a case series (Table 1 and Supporting Informa-
tion Table S2).5,7,9 Controls were mainly from the SNEHD
study (Table 1).9 All cases and controls were resident in Scot-
land or the north of England at the time of diagnosis or
recruitment, respectively.9 Participants were included if sufﬁ-
cient germline DNA was available for HLA typing and cases
were included only if EBV status of tumors, deﬁned by EBV-
encoded small RNA (EBER) in situ hybridisation or LMP1
immunohistochemistry, was known. The ﬁnal study included
503 patients (155 EBV-positive, 348 EBV-negative) and 347
controls. Self-reported history of IM was available for 97% of
controls and 60% of patients.7,9 Ethical approval was
obtained from Research Ethics Committees and all partici-
pants provided informed consent.
HLA typing and genotyping
Intermediate-resolution typing of HLA-A, C, B and DRB1
genes was performed on all participants (hereafter referred to
as the larger dataset) at Anthony Nolan using locus-speciﬁc
PCR followed by sequence speciﬁc oligonucleotide hybridiza-
tion (One Lambda, Canoga Park, CA). This generates a list
of possible alleles, including common, well-deﬁned and rare
alleles, which differ in the second ﬁeld of the allele descriptor;
the most likely common allele was assigned, unless stated
What’s new?
Strong evidence exists for associations between HLA alleles and classical Hodgkin lymphoma (cHL). Analysis is however com-
plicated by the linkage disequilibrium within the MHC region and data suggesting that associations with Epstein-Barr virus
(EBV)-positive and negative cHL are distinct. In the largest study to date to investigate associations between EBV-stratified
cHL subgroups and directly typed HLA alleles, the authors extend associations with EBV-positive cHL to novel HLA class II
alleles, which are associated with decreased disease risk. For EBV-negative disease, the class II SNP rs6903608 remains the
strongest predictor of risk after adjusting for the effects of common HLA alleles.
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otherwise. HLA-DQA1, DQB1 and DPB1 typing was per-
formed at an earlier time-point in GMT’s laboratory on par-
ticipants in the SNEHD study (smaller dataset), as previously
described15,28230 (Table 2). Genotyping results at SNPs
rs6903608, rs2248462 and rs2395185 were available for
>90% of individuals from previous GWAS.23,24
Statistical analysis
All alleles with frequency 5% in any group (controls, EBV-
positive cases, EBV-negative cases) were selected for analysis.
B*35:01, control allele frequency5 4.5%, was also included
because of data related to EBV-speciﬁc immune responses and
DQB1*03:03, control allele frequency5 1.8%, was added
because of previous associations with cHL risk.6,17,27 This
resulted in a total of 44 alleles in analyses, unless otherwise
stated (Supporting Information Tables S3 and S4). We assessed
whether allele carrier frequencies, i.e., the proportion of individ-
uals who possess a particular allele, among controls were repre-
sentative of the northern UK population by using Fisher exact
tests to compare controls with blood donors from Newcastle,
Table 2. Number of cases and controls typed at each HLA locus
Controls
N (%)
All cases
N (%)
EBV1ve
cases N (%)
EBV2ve
cases N (%)
Total 347 503 155 348
HLA-A 347 (100%) 502 (99.8%) 154 (99%) 348 (100%)
HLA-C 347 (100%) 499 (99%) 154 (99%) 345 (99%)
HLA-B 347 (100%) 500 (99%) 154 (99%) 346 (99%)
HLA-DRB1 311 (90%) 469 (93%) 144 (93%) 325 (93%)
HLA-DQA1 313 (90%) 253 (50%) 75 (48%) 178 (51%)
HLA-DQB1 308 (89%) 246 (49%) 71 (46%) 175 (50%)
HLA-DPB1 305 (88%) 246 (49%) 73 (47%) 173 (50%)
rs6903608 341 (98%) 475 (94%) 146 (94%) 329 (95%)
rs2248462 322 (93%) 464 (92%) 141 (91%) 323 (93%)
rs2395185 339 (98%) 473 (94%) 147 (95%) 326 (94%)
Complete typing data for HLA-A, C, B and DRB1 were available for 311 controls and 469 cases (larger dataset) and complete data for A, C, B, DRB1,
DQA1, DQB1 and DPB1 were available for 287 controls and 225 cases (smaller dataset). All cases, all cHL cases; EBV1ve cases, EBV-positive cHL
cases; EBV-ve cases, EBV-negative cHL cases; N, number.
Table 1. Numbers of controls and cases by sex, age, histological subtype, history of IM and study
Controls
N (%)
All cases
N (%)
EBV1ve
cases N (%)
EBV-ve
cases N (%)
Total participants 347 503 155 348
Sex Female 144 (41) 225 (45) 49 (32) 176 (51)
Male 203 (59) 278 (55) 106 (68) 172 (49)
Age group (years) 15-34 131 (38) 272 (54) 61 (39) 211 (61)
35-49 81 (23) 99 (20) 31 (20) 68 (20)
50 135 (39) 132 (26) 63 (41) 69 (20)
Histological subtype Mixed cellularity 115 (23) 63 (41) 52 (15)
Nodular sclerosis 353 (70) 79 (51) 274 (79)
Other 35 (7) 13 (8) 22 (6)
Self-reported IM Not recorded 12 201 70 131
No 316 (94) 268 (89) 72 (85) 196 (90)
Yes 19 (6) 34 (11) 13 (15) 21 (10)
Study SNEHD 320 (92) 283 (56) 82 (53) 201 (58)
YHHCCS 27 (8) 41 (8) 10 (6) 31 (9)
ITCH 0 (0) 179 (36) 63 (41) 116 (33)
All cases, all cHL cases; EBV1ve cases, EBV-positive cHL cases; EBV-ve cases, EBV-negative cHL cases; N, number; IM, infectious mononucleosis;
SNEHD, Scotland and Newcastle Epidemiological study of Hodgkin’s Disease; YHHCCS, Young adult Hodgkin disease and Haematological malignancy
Case Control Study; ITCH, Investigation of The Cause of Hodgkin lymphoma, a cHL case series.
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Leeds and Shefﬁeld (http://www.allelefrequencies.net,
n512,518 for HLA-A, B and DRB1 and n5 7,568 for HLA-
C).31 Similar large datasets were not available for DQ and
DPB1 alleles. v2 tests of deviation from Hardy-Weinberg equi-
librium (HWE) were performed on the seven HLA loci, pool-
ing alleles with frequency< 15%, and the three MHC SNPs.
We tested the association between carrier status of each of
the HLA alleles and each of the four cHL outcomes, compris-
ing three case:control comparisons (with cases deﬁned as “all
cHL,” EBV-positive cHL and EBV-negative cHL) and one
case:case comparison (EBV-positive vs. EBV-negative cHL).
Adjustment for multiple testing used the Bonferroni method
where the signiﬁcance level was 0.05 divided by the effective
number of tests.32 SNPs were tested for association with each
outcome assuming an additive model.
We next tested whether HLA-B*08:01 and B*35:01, two
alleles known to elicit immunodominant EBV-speciﬁc CTL
responses, are associated with decreased risk of EBV-positive
cHL. Associations between DRB1*15:01, DQB1*06:02,
DPB1*02:01 and DPB1*03:01 and “all cHL” and EBV-
stratiﬁed subgroups were also examined as these alleles have
been previously associated with cHL.12,13,15217,27 This group
of analyses was adjusted for effects of sex, age group (15–34,
35-49, 50 years) and additive effects of HLA-A*01:01 and
A*02:01, since we previously reported that these differed in
the EBV-positive and negative patients in this dataset.21 A
carrier effect (i.e., possession of a particular allele) was tested
initially and, where this proved signiﬁcant (p< 0.05), additive
(i.e., per allele) and homozygote effects were examined; a two
point drop in the corrected Akaike information criterion33
was considered evidence for a better ﬁt. Findings reported by
Huang et al. (2012) were tested in unadjusted analyses fol-
lowing grouping of alleles into broad HLA serotypes.22
Allele selection regression modeling
The aim of this analysis was to select the subset of alleles
that best predicts each of the four cHL outcomes described
above. We used a Bayesian variable selection regression
method34 that has two advantages over traditional frequentist
model selection methods. First, it explores all possible candi-
date models, whereas only a fraction of models are assessed
by the commonly used method of stepwise regression. Sec-
ond, it directly estimates the probability that an allele is asso-
ciated with the outcome (the posterior probability of
association or PPA). A p-value, by contrast, cannot be inter-
preted as a measure of support without consideration of
power.35 The prior probability of each variable being associ-
ated with the outcome was set at 5%. This choice of prior
was validated by estimating the false discovery rate using per-
mutations (Supporting Information). The low prior probabil-
ity of association acts analogously to a multiple testing
penalty by allowing only alleles supported by the strongest
evidence to be selected.35 A PPA 90% was considered to
provide strong support and a PPA of 502 90% moderate
support for association.
Models included 44 HLA alleles and the SNPs, rs6903608,
rs2248462 and rs2395185. Independent variables ﬁtted in
regression models for variable selection were: sex; age group;
and carrier status of each HLA allele/SNP. To allow deviation
from a codominant model to be detected, homozygote effects
were also included in models if at least ﬁve individuals in
either comparison group were homozygous for the allele.
Alleles with a PPA 50% were selected and reﬁtted in a Firth
logistic regression model,36 with adjustment for effects of sex
and age group and, where EBV-positive patients were
included, the additive effects of A*01:01 and A*02:01. Model
selection was run on both the larger and smaller datasets and
results amalgamated as described in Supporting Information
and Table S1. For completeness, modeling was also performed
using only the 44 HLA alleles without inclusion of the SNPs.
Based on allele selection, the haplotypes A*01:01-C*06:02-
B*37:01 and rs6903608C-DRB1*15:01-DQB1*06:02 were
added to ﬁnal models of EBV-positive and EBV-negative
cHL, respectively. Haplotypes were inferred by the single-
imputation method,37 based on haplotype probabilities esti-
mated using the expectation-maximization algorithm imple-
mented in the haplo.stats package38 for R.39 To determine
whether effects of HLA alleles and IM were independent,
self-reported history of IM was added to the ﬁnal logistic
regression analysis of EBV-positive cHL.
Power analysis
We estimated that our study was sufﬁciently sensitive to
detect positive HLA allele-disease associations with odds
ratios (ORs) in the range 22 2.5 or greater (0.32 0.5 or less
for negative associations), assuming a codominant model and
adjusting for multiple testing (Supporting Information).
Results
Complete data for HLA-A, C, B and DRB1 alleles were avail-
able for 311 controls and 469 patients (larger dataset) and
complete data for A, C, B, DRB1, DQA1, DQB1 and DPB1
alleles were available for 287 controls and 225 patients
(smaller dataset; Table 2). Forty-four HLA alleles, comprising
forty-two that passed the allele-frequency threshold for inclu-
sion plus B*35:01 and DQB1*03:03, were analysed. Genotype
and carrier frequencies of these HLA alleles and allele fre-
quencies of the three SNPs are presented in Supporting Infor-
mation Tables S32S5. Carrier frequencies of HLA-A, C, B
and DRB1 alleles in controls did not differ signiﬁcantly from
those in geographically similar blood donor populations (data
not shown). Carrier frequencies of DQB1 and DPB1 alleles
were also similar to those reported in small datasets from the
northwest of England, with the exception of DQB1*03:04
which was present at a higher frequency in the current study
than in other datasets (http://www.allelefrequencies.net/; Sup-
porting Information Table S4). Genotype frequencies among
controls deviated from HWE at two of seven HLA loci,
DQB1 (p5 0.014) and DPB1 (p5 0.0032) and none of the
three SNP loci (Supporting Information Table S6). Since
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controls were drawn from a restricted geographical area and
because only two loci were affected, population stratiﬁcation
is an unlikely explanation for this departure from HWE.
Associations between the carrier status of each of the 44
HLA alleles and each of the four cHL outcomes were tested in
unadjusted analyses, using an adjusted signiﬁcance threshold
of 0.0015 to account for multiple testing (Table 3, Supporting
Information Methods and Table S4). Increased risk of EBV-
positive cHL was associated with A*01:01 (p5 9.7 3 1029),
C*07:01 (p5 5.8 3 1026), B*08:01 (p5 8.9 3 1028) and
DRB1*03:01 (p5 6.4 3 1025; Table 3). Increased risk of EBV-
negative cHL was associated with C*07:02 (p5 0.00072),
B*07:02 (p5 0.00023), DRB1*15:01 (p5 0.00083) and
DQB1*06:02 (p5 1.6 3 1025) whereas DRB1*07:01
(p5 0.00027) was associated with decreased risk (Table 3).
Consistent with previous results, rs6903608C was associated
with an increased risk of “all cHL” and EBV-negative cHL.23,24
rs2248462A and rs2395185T were associated with a decreased
risk of “all cHL” with no evidence of heterogeneity by EBV sta-
tus (Supporting Information Table S5).
Associations between B*08:01 and B*35:01 and EBV-
positive cHL were investigated after adjusting for sex, age
group and the additive effects of A*01:01 and A*02:01; results
are presented in Supporting Information Table S7. B*08:01 was
associated with a signiﬁcantly increased risk of EBV-positive
cHL and this was best modelled as an additive or homozygote,
rather than carrier, effect [ORhomozygote5 4.7; 95% conﬁdence
interval (CI), 1.92 13.1]. B*08:01 was also associated with “all
cHL” (ORhomozygote5 4.5; 95% CI, 1.9–11.9) and there was no
evidence of heterogeneity by tumor EBV status (p5 0.97).
B*35:01 was not signiﬁcantly associated with EBV-positive
cHL (ORcarrier5 0.7; 95% CI, 0.3–1.6).
Figure 1. Forest plot showing final models for EBV-positive and EBV-negative cHL. Panel A. EBV-positive Hodgkin lymphoma. Panel B. EBV-
negative Hodgkin lymphoma. The set of allele effects that best predicted EBV-positive and EBV-negative Hodgkin lymphoma cases was
selected from 44 HLA alleles and three selected MHC SNPs. Effects with a posterior probability of association (PPA)50%, estimated in a
Bayesian variable selection model, were selected. The ORs and 95% CIs presented here were estimated after refitting in a Firth logistic
regression model. For EBV-positive Hodgkin lymphoma, HLA-A*01:01 and A*02:01 were included as adjustment variables and were not sub-
ject to variable selection; analyses were adjusted for sex and age group. Symbol size reflects allele frequency.
Table 3. Significant associations between carrier frequencies of HLA alleles and “all cHL” and EBV-stratified subgroups in unadjusted
analyses
HLA allele
Cases
vs. controls
EBV1 cases
vs. controls
EBV2 cases
vs. controls
EBV1 cases
vs. EBV- cases
OR (CI), p value OR (CI), p value OR (CI), p value OR (CI), p value
A*01:01 1.4 (1.1, 1.8), 0.020 3.1 (2.1, 4.6), 9.7e-9 1.0 (0.7, 1.3), 0.85 3.2 (2.2, 4.7), 4e-9
C*07:01 1.5 (1.1, 2.0), 0.0045 2.5 (1.7, 3.6), 5.8e-6 1.2 (0.9, 1.7), 0.24 2.0 (1.4, 3.0), 0.00033
C*07:02 1.3 (1.0, 1.8), 0.055 0.7 (0.4, 1.1), 0.092 1.7 (1.3, 2.4), 0.00072 0.4 (0.2, 0.6), 1.8e-5
C*06:02 1.0 (0.7, 1.4), 0.81 1.6 (1.0, 2.5), 0.039 0.7 (0.5, 1.1), 0.11 2.2 (1.4, 3.6), 0.00081
B*08:01 1.6 (1.2, 2.2), 0.0014 3.0 (2.0, 4.4), 8.9e-8 1.2 (0.9, 1.7), 0.25 2.4 (1.6, 3.6), 9e-6
B*07:02 1.4 (1.0, 1.9), 0.029 0.7 (0.4, 1.1), 0.098 1.8 (1.3, 2.5), 0.00023 0.4 (0.2, 0.6), 7.3e-6
B*37:01 1.4 (0.7, 2.7), 0.31 2.9 (1.4, 6.1), 0.0038 0.8 (0.4, 1.7), 0.55 3.7 (1.7, 8.2), 0.00073
DRB1*03:01 1.5 (1.1, 2.0), 0.012 2.3 (1.5, 3.5), 6.4e-5 1.2 (0.9, 1.7), 0.29 1.9 (1.3, 2.9), 0.0014
DRB1*15:01 1.2 (0.9, 1.7), 0.17 0.5 (0.3, 0.8), 0.0021 1.7 (1.3, 2.4), 0.00083 0.3 (0.2, 0.4), 1.5e-8
DRB1*07:01 0.5 (0.4, 0.8), 0.00075 0.7 (0.4, 1.1), 0.15 0.5 (0.3, 0.7), 0.00027 1.5 (0.9, 2.5), 0.14
DQB1*06:02 1.5 (1.1, 2.2), 0.021 0.3 (0.1, 0.7), 0.0020 2.4 (1.6, 3.5), 1.6e-5 0.1 (0.1, 0.3), 1.7e-8
EBV1 cases: EBV-positive cHL cases; EBV2 cases: EBV-negative cHL cases; vs: versus; OR: odds ratio; CI: confidence interval. Results in bold are
significant after correction for multiple testing; results in italics have p values<0.05. Alleles are included in the table only if the p value for one of
the outcomes was significant after correction for multiple testing.
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Consistent with previous data, DRB1*15:01 was associated
with an increased risk of EBV-negative cHL and this was
best modeled as an additive or homozygote effect (ORper-
allele5 1.7; 95% CI, 1.3–2.3; Supporting Information Table
S7). The association with EBV-positive cHL was in the oppo-
site direction (ORcarrier5 0.5; 95% CI, 0.3–0.8) and differen-
ces by EBV status were signiﬁcant (p5 1.2 3 1025). Similar
results were obtained for DQB1*06:02, which is in LD with
DRB1*15:01 (Supporting Information Table S7). There was
an increased risk of EBV-negative cHL (ORhomozygote5 5.0;
95% CI, 2.5–10.3) and a decreased risk of EBV-positive cHL
(ORcarrier5 0.4; 95% CI, 0.1–0.8). Differences by EBV status
were signiﬁcant (p5 2.5 3 1026). We did not ﬁnd a statisti-
cally signiﬁcant association with DPB1*02:01, although there
was signiﬁcant heterogeneity by tumor EBV status
(p5 0.040). Both EBV-positive and negative patients were
more likely to carry DPB1*03:01 than controls but differences
were not signiﬁcant (Supporting Information Table S7).
For comparison with published data, associations between
cHL and allele frequencies, expressed as broad serotypes,
were investigated in unadjusted analyses (Supporting Infor-
mation Table S8 and Supporting Information Fig. S1).22 For
“all cHL,” we corroborated associations with DR2 and DR7
but signiﬁcant associations with DR5 and the less common
alleles B5 and B37, were not detected. For EBV-positive
patients, we conﬁrmed an increased frequency of A1 and B37
and a decreased frequency of A2. An increased frequency of
the less common DR10 allele was detected but this associa-
tion was not statistically signiﬁcant. For EBV-negative
patients, an increased frequency of DR2 and decreased fre-
quency of DR7 were corroborated; there was no signiﬁcant
association with DR5.
Allele selection regression modeling
HLA alleles and SNPs associated with “all cHL,” EBV-
positive cHL, EBV-negative cHL and that distinguish EBV-
positive from EBV-negative cHL, were identiﬁed using a
Bayesian variable selection method.34 Analyses included 44
HLA alleles, modelled as both carrier and homozygote effects,
and three SNPs. The estimated false discovery rates were
24% for PPA 50 and 6.0% for PPA 90%. Thus, 76% and
94% of the allelic effects selected at the 50% and 90% thresh-
olds, respectively, were estimated to be true discoveries. These
estimates suggest that setting the prior probability of associa-
tion at 5% resulted in broadly realistic PPA estimates. Alleles
with PPA 50% were selected and reﬁtted in a Firth logistic
regression model.
EBV-positive cHL
In order of strength of association, the alleles selected by the
model were DPB1*01:01 (PPAcarrier5 88%), A*01:01
(PPAadditive5 84%), B*37:01 (PPAcarrier5 66%) and
DRB1*15:01 (PPAcarrier5 59%). None of the SNPs was
selected, thus suggesting that their effects were accounted for
by HLA alleles. Subsequent Firth logistic regression modeling
indicated that A*01:01 (ORper-allele5 2.49; 95% CI, 1.75–3.59)
and B*37:01 (OR5 2.58; 95% CI, 1.13–6.04) were associated
with increased risk of disease whereas DRB1*15:01 (OR5 0.45;
95% CI, 0.26–0.75) and DPB1*01:01 (OR5 0.22; 95% CI,
0.06–0.65) were associated with decreased risk (Table 4, Fig.
1a). Results of modeling without inclusion of the SNPs looked
similar; the only qualitative difference was that DRB1*03:01
was selected in this model (PPA5 58%) but was dropped fol-
lowing inclusion of the SNPs (PPA5 44%) (Supporting Infor-
mation Table S9).
Because B*37:01 and A*01:01 are in LD, we examined
whether the haplotype A*01:01-C*06:02-B*37:01 was associ-
ated with increased disease risk but found no evidence to
support this hypothesis following adjustment for the effects
of individual alleles (p5 0.13) (Supporting Information Table
S10). Prior IM remained a signiﬁcant risk factor for EBV-
positive cHL after adjusting for the effects of alleles selected
in the above model (OR5 4.51; 95% CI, 1.44–14.04) (Sup-
porting Information Table S11).
We found no evidence that A*02:01 was associated with a
decreased risk of EBV-positive cHL in allele selection model-
ing. There was a deﬁcit of A*02:01-positive carriers in EBV-
associated cases compared to controls and EBV-negative
cases (36 vs. 46 and 50%, respectively) but these differences
were not signiﬁcant after correction for multiple testing (Sup-
porting Information Table S4). In logistic regression model-
ing with adjustment for the effects of sex, age group and the
additive effect of A*01:01 alleles, the additive effect of
A*02:01 was not signiﬁcant in either the case: control or case
series analyses (Supporting Information, Table S12).
EBV-negative cHL
There was strong support for association with the SNP
rs6903608 (PPA5 95%) and moderate support for associations
with DQB1*03:03 (PPAcarrier5 70%), DRB1*03:01
(PPAhomozygote5 67%) and B*15:01 (PPAcarrier5 60%). Associ-
ations remained signiﬁcant in Firth logistic regression model-
ing and all were associated with increased disease risk, as
presented in Table 5 and Figure 1b. In modeling without
Table 4. Final model for EBV-positive Hodgkin lymphoma, adjusted
for sex and age group
Variable PPA OR (95% CI) p-values
HLA-A*01:01 additive# 84% 2.49 (1.75, 3.59) 2.5 3 1027
HLA-A*02:01 additive# 11% 0.97 (0.66, 1.42) 0.89
HLA-B*37:01 carrier 66% 2.58 (1.13, 6.04) 0.024
HLA-DRB1*15:01 carrier 59% 0.45 (0.26, 0.75) 0.0019
HLA-DPB1*01:01 carrier‡ 88% 0.22 (0.06, 0.65) 0.004
Bayesian variable selection modeling was performed on EBV-positive
Hodgkin lymphoma cases versus controls, with inclusion of 44 HLA
alleles and three selected MHC SNPs; alleles with a posterior probabil-
ity of association (PPA) 50% were selected and refitted in a Firth
logistic regression model to generate ORs and CIs. #, adjustment vari-
able, not subject to variable selection; ‡, data derived from analysis
of smaller data set.
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inclusion of the SNPs, only DQB1*06:02
(PPAhomozygote5 67%) and DRB1*07:01 (PPAhomozygote5 64%)
were selected (Supporting Information Table S13).
The C variant of rs6903608 is in LD with DRB1*15:01
(r25 0.5, D’5 1.0) and DQB1*06:02 (r25 0.4, D’5 0.9) and
we therefore addressed whether the haplotype rs6903608C-
DRB1*15:01-DQB1*06:02 is associated with EBV-negative
cHL. Following adjustment for variables in our model, this
haplotype was not signiﬁcantly associated with increased dis-
ease risk when modelled as a homozygote (p5 0.99) or car-
rier (p5 0.98) effect (Supporting Information Table S14).
All cHL
The alleles and SNP selected in the modeling of all case with-
out stratiﬁcation by EBV status were DQB1*03:03
(PPAcarrier5 78%), rs6903608 (Chomozygote PPA5 74%),
DRB1*03:01 (PPAhomozygote5 70%) and DPB1*01:01
(PPAcarrier5 64%), thus reﬂecting associations in the sub-
group analyses. Further details are presented in Supporting
Information Tables S15 and S16.
EBV-positive cHL versus EBV-negative cHL
DRB1*15:01 showed the strongest evidence for heterogeneity
by case group (PPAcarrier5 95%) followed by A*01:01
(PPAadditive5 77%), B*37:01 (PPAcarrier5 68%) and
DQA1*01:02 (PPAcarrier5 59%; Supporting Information Table
S17). DQA1*01:02 is in LD with DRB1*15:01 but associations
were in opposite directions. B*27:05 also reached the thresh-
old for selection (PPAcarrier5 50%) but was not signiﬁcant in
subsequent logistic regression modeling (ORcarrier5 0.47; 95%
CI, 0.17–1.12). Further details are presented in Supporting
Information Tables S17 and S18.
Discussion
There is compeling evidence linking MHC polymorphisms
with risk of cHL10,12,13,15221,23225,27; however, the extensive
LD within the MHC region makes it difﬁcult to identify the
causal alleles. In cHL a proportion of cases are causally asso-
ciated with EBV and the available data suggest that EBV-
positive and negative cHL have distinct MHC associations,
further complicating the analysis.18,20,21,24 The aim of this
study was to identify the HLA alleles that are most likely to
independently inﬂuence cHL risk by performing allele selec-
tion regression modeling with cases stratiﬁed by EBV status.
The results provide further evidence for strong HLA associa-
tions that differ by EBV status of cHL tumors.
In analyses of EBV-positive cHL without adjustment for
effects of other alleles, HLA-A*01:01, C*07:01, B*08:01 and
DRB1*03:01 were all associated with increased disease risk
(Table 3). These alleles are all present on an ancestral HLA
haplotype but following allele selection modeling only
A*01:01 was retained in the model (Table 4 and Fig. 1a).
B*37:01, which has previously been associated with EBV-
positive cHL,22 was also selected by our model and was asso-
ciated with increased disease risk. A*01:01 and B*37:01 are in
LD on the haplotype A*01:01-C*06:02-B*37:01 but the effects
of the individual alleles were independent and remained after
adjusting for the effect of the haplotype (Supporting Informa-
tion Table S10). Two new associations with EBV-positive
cHL were identiﬁed in this analysis. DPB1*01:01 was associ-
ated with a decreased disease risk. This allele has not been
previously linked to cHL and in unadjusted analyses did not
pass the signiﬁcance threshold following correction for multi-
ple testing; however, in our model DPB1*01:01 was the allele
most strongly associated with EBV-positive cHL. There was
also moderately strong evidence for an association between
DRB1*15:01 and decreased disease risk and this was best
modelled as a carrier effect. This contrasts with the situation
in EBV-negative cHL where the additive effect of
DRB1*15:01 alleles was associated with increased risk in
unadjusted analyses.
Since IM is a risk factor for EBV-positive cHL and both
cHL and IM show HLA associations, prior IM was added as
a variable in logistic regression analysis of alleles included in
our model729,21,40,41 (Supporting Information Table S11).
Effects of IM remained signiﬁcant indicating that HLA and
IM are independent risk factors and providing no evidence
for shared genetic susceptibility.
A*02:01 has previously been associated with a decreased
risk of EBV-positive cHL.20222 Although A*02:01 was under-
represented in EBV-positive cHL cases (Supporting Informa-
tion Tables S3 and S4), this would be expected in an unad-
justed comparison even if A*02:01 had no protective effect,
because subjects carrying A*02:01 are less likely to carry
A*01:01, which is a strong risk factor for EBV-positive cHL.
A*02:01 was not independently associated with EBV-positive
cHL in our adjusted analysis and gave OR estimates close to
one in subsequent logistic regression analyses (Table 4 and
Supporting Information Tables S9, S17 and S18). However,
in a larger study that included the patients in the current
study along with cases from Denmark and Sweden, A*02:01
was associated with a decreased risk of EBV-positive cHL
independently of A*01:01.21,24 Similarly, a GWAS that
Table 5. Final model for EBV-negative cHL, adjusted for sex and age
group
Variable PPA OR (95% CI) p-Value
HLA-B*15:01 carrier 60% 1.81 (1.10, 3.02) 0.020
rs6903608 C
homozygote
95% 3.61 (2.16, 6.25) 4.5 3 1027
HLA-DRB1*03:01
homozygote
67% 5.14 (1.80, 17.56) 0.0018
HLA-DQB1*03:03
carrier‡
70% 3.22 (1.26, 8.36) 0.015
Bayesian variable selection modeling was performed on EBV-negative
Hodgkin lymphoma cases versus controls, with inclusion of 44 HLA
alleles and three selected MHC SNPs; alleles with a posterior probabil-
ity of association (PPA) 50% were selected and refitted in a Firth
logistic regression model to generate ORs and CIs. ‡ data derived
from analysis of smaller dataset.
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included most of these cases found a signiﬁcant association
between EBV-positive cHL and the A*02:01-linked SNP
rs6904029 after adjusting for the effects of the A*01:01-linked
SNP rs2734986.24 Neither of these studies found evidence of
heterogeneity of the A*02:01 effect between the UK case
series reported here and the other case series, suggesting that
lack of association in our study could be due to smaller sam-
ple size. Therefore, our results do not cast doubt on the pre-
viously reported A*02:01 associations.
HLA class I and II molecules present peptides from exog-
enous pathogens to CD8 and CD4-positive T-cells, respec-
tively; we therefore believe that HLA associations with EBV-
positive cHL are likely to reﬂect qualitative and/or quantita-
tive differences in the T-cell response to EBV. To date, no
conﬁrmed EBV epitopes or CTL responses restricted by
A*01:01 have been described. Similarly, B*37:01-restricted
CTL responses to peptides from EBNA1, LMP-1 or LMP-2,
the antigens expressed by HRS cells, have not been identi-
ﬁed.6 An association between these alleles and increased dis-
ease risk is therefore plausible; however, A*01:01 is in LD
with B*08:01 and there are robust EBV-speciﬁc responses
restricted through this allele.6 Although the immunodomi-
nant B*08:01-restricted responses are to EBNA3A and the
lytic cycle protein BZLF1,6 an EBNA1 epitope has also been
identiﬁed.42,43 We therefore investigated whether B*08:01
confers any protective effect after adjusting for the effects of
A*01:01 (Supporting Information Table S7); consistent with
Huang et al. (2012), we found no support for this hypothe-
sis.22 Because HLA- B*35:01 also elicits an immunodominant
EBNA1 response, we speciﬁcally included this allele in our
analysis.6 B*35:01 carriers were less frequent among EBV-
positive patients than controls, but differences were not sig-
niﬁcant and this allele was not selected in our model. There-
fore, despite consistent associations between HLA class I
alleles and EBV-positive cHL, there is currently no evidence
that common alleles that elicit good CTL responses confer
protection against this disease.
The identiﬁcation of novel associations between EBV-
positive cHL and DPB1*01:01 and DRB1*15:01 provides evi-
dence that HLA associations with EBV-positive cHL extend
to the class II region. Furthermore, these alleles are associated
with decreased rather than increased disease risk. Class II-
restricted responses to most EBV latent proteins have been
described and many are to EBNA1 epitopes.6 These include a
DRB1*15:01-restricted response, which could explain the
association observed in this study.44 No DPB1*01:01-
restricted EBV responses have been identiﬁed to date, but
HLA restrictions of epitopes presented by class II have been
less extensively characterized than their class I counterparts.
Further laboratory analyses are required to identify
DRB1*15:01 and DPB1*01:01-restricted EBV epitopes and
characterise the associated effector T-cell responses. Such
studies will not only improve our understanding of the natu-
ral history of cHL but will have broader implications for T-
cell based immunotherapy.
In unadjusted analyses of EBV-negative cHL, we con-
ﬁrmed previously described associations with DRB1*07:01,
DRB1*15:01 and DQB1*06:02 (Table 3, Supporting Informa-
tion Table S7)17,22; however, a very different picture emerged
following allele selection analysis, which adjusted for con-
founding among loci due to LD. In modeling without inclu-
sion of the SNPs, DRB1*07:01 was selected along with
DQB1*06:02, which was included at the expense of
DRB1*15:01 (Supporting Information Table S13). After addi-
tion of the SNPs to the analysis, neither DQB1*06:02 nor
DRB1*07:01 passed thresholds for selection and rs6903608
emerged as the strongest predictor of disease status
(PPA5 95%; Table 5, Fig. 1b). This ﬁnding is consistent with
the imputation analysis described by Moutsianas et al.
(2011).27 Three new alleles, B*15:01, DRB1*03:01 and
DQB1*03:03, were also selected by our model and all were
associated with increased risk of disease. DQB1*03:03, which
is in LD with DRB1*07:01, has previously been associated
with decreased rather than the increased disease risk as
described here.17,27
The rs6903608 variant is located close to HLA-DRA and
has been identiﬁed as a cis-expression Quantitative Trait
Locus (eQTL) for HLA-DRA expression (http://genenetwork.
nl/bloodeqtlbrowser),45 raising the possibility that it is
decreased expression of HLA-DR, rather than any particular
allele, that increases risk of EBV-negative cHL. Down-
regulation of HLA class II on HRS cells is a characteristic
feature of EBV-negative cHL, occurring in the majority of
cases.46 Although this is an attractive mechanism that may
allow HRS cells to evade immune destruction, it remains pos-
sible that rs6903608 is in LD with another MHC gene that is
the critical risk factor. Further analysis of the MHC region is
required to determine the biological mechanism underlying
the strong association with this SNP.
Alleles selected in modeling of “all cases” versus controls
simply reﬂected those in the ﬁnal models of EBV-positive and
negative disease (Supporting Information Tables S15 and S16).
Similarly, alleles that best discriminated EBV-positive from
EBV-negative disease were largely those associated with EBV-
positive cHL (Supporting Information Tables S17 and S18).
This is the largest study examining HLA associations with
EBV-stratiﬁed cHL subgroups using directly typed HLA
alleles that has been performed thus far. In preliminary anal-
yses we conﬁrmed that our controls were representative of
the northern UK population from which patients originated.
In unadjusted analyses, we also validated previously reported
associations with cHL including the main ﬁndings reported
by Huang et al. (2012).17,22 Associations with DPB1*02:01
and DPB1*03:01 were not statistically signiﬁcant in this anal-
ysis although risks, at least for EBV-negative cHL, were in
the same direction as previously reported.13 Overall, these
comparisons indicated that this was a robust dataset for fur-
ther analysis, i.e., allele selection modeling. However,
although the study was relatively large, it included only 155
EBV-positive cHL cases so that there was insufﬁcient power
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to detect weak associations (i.e., those with ORs between 0.5
and 2). Sensitivity was considerably less for DQ and DP
alleles, where only half of the cases were typed (Table 2 and
Supporting Information). In addition, DQB1 and DPB1
alleles in controls were not in HWE, as assessed by the geno-
types of the most common alleles (Supporting Information
Table S6). The cause of this is unclear but population stratiﬁ-
cation and selection appear unlikely mechanisms.47 These
two HLA loci, along with DQBA1, were genotyped at an ear-
lier time-point than the other four loci and we favor the idea
that some rare alleles have escaped detection, thus leading to
an apparent excess of homozygotes. Carrier frequencies of
DQB1 and DPB1 alleles were generally similar to those in
comparable studies and identical HLA typing methods were
applied to cases and controls. Deviation from HWE is there-
fore unlikely to have affected the overall results; nevertheless,
some caution should be exercised in the interpretation of
ﬁndings related to DQB1 and DPB1.
In conclusion, our data provide further evidence that the
natural histories of EBV-positive and -negative cHL are dif-
ferent, underscoring the importance of analysing EBV-
stratiﬁed subgroups in biological studies of cHL. We show
that associations between EBV-positive cHL and A*01:01 and
B*37:01 are independent and identify novel associations with
the class II alleles DRB1*15:01 and DPB1*01:01. For EBV-
negative cHL, we show that the class II SNP rs6903608
remains the strongest predictor of disease after adjusting for
the effects of common HLA alleles.
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